Sandoz biosimilar expansion to initially rely on external assets
Sandoz plans to expand its biosimilar-drug portfolio over the next decade and a half, with the initial push relying on external assets, according to J.P. Morgan analysts.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.